MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

PHR.US

8.32

-27.08%↓

MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

PHR.US

8.32

-27.08%↓

MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

PHR.US

8.32

-27.08%↓

MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

PHR.US

8.32

-27.08%↓

MDT

86.56

+0.83%↑

113.95

+1.74%↑

VEEV

175.31

+0.07%↑

HQY

83.18

+1.87%↑

PHR.US

8.32

-27.08%↓

Начало・Списък с акции・Integra LifeSciences Holdings Corp

Integra LifeSciences Holdings Corp

Затворен

СекторЗдравеопазване

9.43 3.74

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

8.86

Максимум

9.44

Ключови измерители
By Trading Economics
Приходи	3.7M -1.7M
Продажби	33M 435M
Марж на печалбата	-0.392
Служители	4,427
EBITDA	12M 66M

Препоръки
By TipRanks
Препоръки	Продай
12-месечна прогноза	+23.36% upside

Дивиденти
By Dow Jones
Следващи печалби	4.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-205M 711M
Предишно отваряне	5.69
Предишно затваряне	9.43

Настроения в новините

By Acuity

100%

330 / 349 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

12.75 / 16.41 Подкрепа & съпротива

Integra LifeSciences Holdings Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

31.03.2026 г., 23:31 ч. UTC

Горещи акции

Stocks to Watch: Nike, RH, NCino

31.03.2026 г., 22:35 ч. UTC

Печалби

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1.04.2026 г., 00:00 ч. UTC

Придобивния, сливания и поглъщания

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31.03.2026 г., 23:50 ч. UTC

Придобивния, сливания и поглъщания

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31.03.2026 г., 23:43 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31.03.2026 г., 23:33 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31.03.2026 г., 23:21 ч. UTC

Печалби

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31.03.2026 г., 23:14 ч. UTC

Пазарно говорене

Печалби

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31.03.2026 г., 23:12 ч. UTC

Пазарно говорене

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31.03.2026 г., 22:36 ч. UTC

Печалби

China Vanke 2025 Loss Widens >000002.SZ

31.03.2026 г., 22:36 ч. UTC

Печалби

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31.03.2026 г., 22:36 ч. UTC

Печалби

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31.03.2026 г., 22:36 ч. UTC

Печалби

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31.03.2026 г., 22:36 ч. UTC

Печалби

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31.03.2026 г., 21:46 ч. UTC

Придобивния, сливания и поглъщания

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31.03.2026 г., 21:36 ч. UTC

Пазарно говорене

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31.03.2026 г., 21:35 ч. UTC

Печалби

Nike Expects China Sales Down 20% in 4Q, CFO Says

31.03.2026 г., 21:35 ч. UTC

Печалби

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31.03.2026 г., 21:35 ч. UTC

Печалби

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31.03.2026 г., 21:33 ч. UTC

Придобивния, сливания и поглъщания

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31.03.2026 г., 21:33 ч. UTC

Печалби

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31.03.2026 г., 21:32 ч. UTC

Печалби

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31.03.2026 г., 21:28 ч. UTC

Печалби

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31.03.2026 г., 21:26 ч. UTC

Печалби

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31.03.2026 г., 21:25 ч. UTC

Печалби

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31.03.2026 г., 21:24 ч. UTC

Пазарно говорене

Печалби

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31.03.2026 г., 21:22 ч. UTC

Печалби

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31.03.2026 г., 21:22 ч. UTC

Печалби

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31.03.2026 г., 21:21 ч. UTC

Печалби

Nike's Digital Channel Still Too Promotional, CFO Says

31.03.2026 г., 21:20 ч. UTC

Печалби

Nike CEO: Converse Remains Important to Portfolio

Сравнение с други в отрасъла

Ценова промяна

Integra LifeSciences Holdings Corp Прогноза

Ценова цел

By TipRanks

23.36% нагоре

12-месечна прогноза

Среден 11.25 USD 23.36%

Висок 13 USD

Нисък 9 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Integra LifeSciences Holdings Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Продай

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на Integra LifeSciences Holdings Corp през последните 3 месеца.

Техническа оценка

By Trading Central

12.75 / 16.41Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Настроение

By Acuity

330 / 349 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Integra LifeSciences Holdings Corp

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.